A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: A systematic review of 137 randomized controlled trials with 39 845 patients

Acta Diabetologica

Volumn 51, Issue 2, 2014, Pages 305-311

  Esposito, Katherine ^a   Chiodini, Paolo ^a   Ceriello, Antonio ^b   Giugliano, Dario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

HbA1c; Nomogram; Noninsulin antidiabetic drugs; Systematic review; Target; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLINIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; DRUG EFFICACY; HUMAN; NOMOGRAM; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; DIABETES MELLITUS, TYPE 2; META ANALYSIS; METABOLISM;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; NOMOGRAMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84898466360     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-012-0370-9     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention (2009) Diabetes data and trends. http://www.cdc.gov/diabetes/statistics/incidence/fig1.htm. Accessed 1 Oct 2011
2. National Center for Health Statistics (2009) Health, United States: with special feature on medical technology. Hyattsville, MD
3. Executive Summary (2011) Standards of medical care in diabetes. Diabetes Care 34(Suppl 1):S4-S10
4. Nathan DM, Buse J, Davidson MB et al (2009) American diabetes association; European association for the study of diabetes. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care 32(1):193-203
5. Rodbard HW, Jellinger PS, Davidson JA et al (2009) Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15(7):540-559
6. Canadian Diabetes Association (2008) Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 32(Suppl 1):S1-S201
7. Centre for Clinical Practice at NICE (2009) Type 2 diabetes: newer agents. NICE short clinical guideline 87 Issue date
8. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151(4):W65-W94
9. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1-12
10. Stuart A, Ord JK (1994) Kendall's advanced theory of statistics, 6th edn. Edward Arnold, London
11. Deeks JJAD, Bradburn MJ (2001) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger MD-SG, Altman DG (eds) Systematic reviews in health care. BMJ Publishing, London, pp 285-312
12. Van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21(4):589-624
13. Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18(20):2693-2708
14. Higgins JP, Thompson SG (2004) Controlling the risk of spurious findings from meta-regression. Stat Med 23(11):1663-1682
15. Cimino A, Giorda C, Meloncelli I, et al (2006) AMD annals: quality indicators in diabetes care in Italy. http://ebookbrowse.com/2006-annali-amd- ita-pdf-d70659475. p 30. Last accessed Sept 2011
16. Alexander GC, Sehgal NL, Moloney RM, Stafford RS (2008) National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 168(19):2088-2094
17. Phung OJ, Scholle JM, Talwar M, Coleman CI (2010) Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303(14):1410-1418
18. Bennett WL, Maruthur MN, Singh S et al (2011) Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154(9):602-613
19. Esposito K, Cozzolino D, Bellastella G et al (2011) Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diab Obes Metab 13(7):594-603
20. National Committee for Quality Assurance: The state of health care quality 2010 report [article online]. Washington, DC, National Committee for Quality Assurance. Available from http://web.ncqa.org. Last accessed April 2011. http://www.ncqa.org/portals/0/state%20of%20health%20care/2010/sohc%202010%20- %20full2.pdf
21. Selvin E, Bolen S, Yeh H-C et al (2008) Cardiovascular outcomes in trials of oral diabetes medications. Arch Intern Med 168(19):2070-2080
22. Fu AZ, Qiu Y, Davies MJ, Radican L, Engel SS (2011) Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diab Obes Metab 13(8):765-769